Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3.
Bozinoff N, DeBeck K, Milloy MJ, et al. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada. Drug Alcohol Depend. 2018;193:42–7.
Bodkin C, Bondy S, Regenstreif L, Kiefer L, Kouyoumdjian F. Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015–2018: a repeated cross-sectional analysis. BMJ Open. 2021;11(11):e048944.
Correctional Service Canada. Opioid Agonist Treatment. Ottawa, Ontario: Correctional Service Canada; 2021.
Caulkins JP, Gould A, Pardo B, Reuter P, Stein BD. Opioids and the criminal justice system: new challenges posed by the modern opioid epidemic. Annu Rev Criminol. 2021;4(1):353–75.
Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.
The British Columbia Centre on Substance Use (BCCSU). A guideline for the clinical management of opioid use disorder. Vancouver, BC: The British Columbia Centre on Substance Use (BCCSU); 2017.
Bruneau J, Ahamad K, Goyer M-È, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190(9):E247–57.
Centre for Addiction and Mental Health (CAMH). Opioid agonist therapy: a synthesis of canadian guidelines for treating opioid use disorder. Toronto, Ontario: Centre for Addiction and Mental Health (CAMH); 2021.
Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment improvement protocol 63: medications for opioid use disorder. US Department of Health and Human Services; 2021.
Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009;10(11):1727–40.
Santo T, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78:979.
Pearce LA, Min JE, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;368:m772.
Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int J Drug Policy. 2021;93:103237.
Government of Canada. Opioid related harms in Canada. Ottawa, Ontario: Government of Canada; 2020.
Gomes T, Murray R, Kolla G, et al. Changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic. Toronto, Ontario: Public Health Ontario (PHO); 2021.
Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019;74:257–65.
Davis CS, Samuels EA. Opioid policy changes during the COVID-19 pandemic - and beyond. J Addict Med. 2020;14(4):e4–5.
Davis CS, Carr DH. Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. Int J Drug Policy. 2019;73:42–8.
Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after federal oversight. Can J Psychiatry. 2017;62(7):444–50.
Lam V, Sankey C, Wyman J, Zhang M. COVID-19 opioid agonist treatment guidance. Toronto, Ontario: Centre for Addiction and Mental Health (CAMH), Mentoring, Education, and Clinical Tools for Addiction Primary Care Hospital Integration (META-PHI), and the Ontario Medical Assocation (OMS); 2021.
McEachern J, Adye-White L, Priest KC, et al. Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy. Int Jurnal of Drug Policy. 2019;64:30–3.
Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. “It’s like ‘liquid handcuffs”: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients’ lives. Harm Reduct J. 2021;18(1):88.
Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19(6):35.
Substance Abuse and Mental Health Services Administration (SAMHSA). Federal guidelines for opioid treatment programs. Rockville, M.D.: Substance Abuse and Mental Health Services Administration; 2015.
Binswanger IA, Stern M, Deyo R, et al. Release from prison: a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.
Merrall EL, Kariminia A, Binswanger IA, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545–54.
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.
Wakeman SE, Rich JD. Substance use disorders and avoidable mortality after prison. Lancet Psychiatry. 2015;2(5):369–70.
Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS ONE. 2013;8(4):e60600.
Groot E, Kouyoumdjian FG, Kiefer L, et al. Drug toxicity deaths after release from incarceration in Ontario, 2006–2013: review of coroner’s cases. PLoS ONE. 2016;11(7):e0157512.
Kouyoumdjian FG, Schuler A, Matheson FI, Hwang SW. Health status of prisoners in Canada. Can Fam Phys. 2016;62(3):215–22.
Kouyoumdjian FG, Kiefer L, Wobeser W, Gonzalez A, Hwang SW. Mortality over 12 years of follow-up in people admitted to provincial custody in Ontario: a retrospective cohort study. CMAJ Open. 2016;4(2):E153-161.
Perry AE, Neilson M, James M-S, et al. Pharmacological interventions for drug-using offenders. Cochrane Database Syst Rev. 2015;6.
Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions, and outcomes among incarcerated persons: a systematic review. PLoS Med. 2019;16(12):e1003002.
Sharma A, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Schwartz RP. Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Subst Abuse Rehabil. 2016;7:27–40.
Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abuse Treat. 2019;99:32–43.
Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiat. 2018;75(4):405–7.
Farrell MacDonald S, MacSwain M-A, Cheverie M, Tiesmaki M, Fischer B. Impact of methadone maintenance treatment on women offenders’ post-release recidivism. Eur Addict Res. 2014;20(4):192–9.
Gisev N, Bharat C, Larney S, et al. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. Lancet Public Health. 2019;4(7):e334–42.
Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018;113(4):656–67.
Correctional Service Canada. Commissioner's Directive 712-4: Release Process. Ottawa, Ontario: Correctional Service Canada; 2019.
Hu C, Jurgutis J, Edwards D, et al. “When you first walk out the gates… where do [you] go?” Barriers and opportunities to achieving continuity of health care at the time of release from a provincial jail in Ontario. PLoS ONE. 2020;15(4):e0231211.
Jamin D, Vanderplasschen W, Sys O, et al. “My first 48 hours out”: drug users’ perspectives on challenges and strategies upon release from prison. Harm Reduct J. 2021;18(1):32.
Velasquez M, Flannery M, Badolato R, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addict Sci Clin Pract. 2019;14(1):37.
Owens MD, Chen JA, Simpson TL, Timko C, Williams EC. Barriers to addiction treatment among formerly incarcerated adults with substance use disorders. Addict Sci Clin Pract. 2018;13(1):19.
Correctional Service Canada (CSC). The correctional plan. Ottawa, Ontario: Correctional Service Canada; 2020.
Dong KR, Must A, Tang AM, Beckwith CG, Stopka TJ. Competing priorities that rival health in adults on probation in Rhode Island: substance use recovery, employment, housing, and food intake. BMC Public Health. 2018;18(1):289.
Bunting AM, Oser CB, Staton M, Eddens KS, Knudsen H. Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: a social ecological approach. Addict Sci Clin Pract. 2018;13(1):23.
Fazel S, Hayes AJ, Bartellas K, Clerici M, Trestman R. Mental health of prisoners: prevalence, adverse outcomes, and interventions. Lancet Psychiatry. 2016;3(9):871–81.
Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. Addiction. 2017. https://doi.org/10.1111/add.13877.
Fischer B, Butler A, Russell C. Commentary on Fazel et al. High levels of substance use disorders among correctional inmates—some implications for interventions of the review data from Fazel et al. Addiction. 2017;112(10):1740–41.
Stewart LA, Nolan A, Thompson J, Power J. Social determinants of health among Canadian inmates. Int J Prison Health. 2018;14(1):4–15.
Sugarman OK, Bachhuber MA, Wennerstrom A, Bruno T, Springgate BF. Interventions for incarcerated adults with opioid use disorder in the United States: a systematic review with a focus on social determinants of health. PLoS ONE. 2020;15(1):e0227968.
Correctional Service Canada. Comunity-based residential facilities (CBRFs). Ottawa, Ontario: Correctional Service Canada; 2018.
Maier KH. Half way to freedom: the role of halfway houses in Canada's Penal Landscape, University of Toronto (Canada); 2018.
Kennedy-Hendricks A, Bandara S, Merritt S, Barry CL, Saloner B. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision. Drug Alcohol Depend. 2021;226:108881.
Executive Director Federal Halfway House in Ontario. Canadian Federal Halfway House OAT Medication Policies. Personal Communication; 2021.
Russell C, Pang M, Nafeh F, et al. Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada. Int J Qual Stud Health Well-Being. 2021.
Special Advisory Committee on the Epidemic of Opioid Overdoses. National Report: Opioid Related Harms in Canada. Ottawa, ON: Government of Canada and Public Health Agency of Canada; 2020.
Kosten TR, Petrakis IL. The hidden epidemic of opioid overdoses during the coronavirus disease 2019 pandemic. JAMA Psychiat. 2021;78(6):585–6.
British Columbia Centre on Substance Use (BCCSU). Risk mitigation in the context of dual public health emergencies. Vancouver, B.C.: British Columbia Centre on Substance Use (BCCSU); 2020.
Bruneau J, Rehm J, Wild TC, et al. Telemedicine support for addiction services: national rapid guidance document. Montreal, Quebec: Canadian Research Initiative in Substance Misuse; May 15th, 2020.
Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study. J Subst Abuse Treat. 2021;129:108374.
Sproule B, Zhang M. Update on opioid use disorder treatment. Ontario College of Pharmacists; 2021.
College of Physicians and Surgeons Ontario (CPSO). Methadone maintenance treatment policy rescinded. Toronto, Ontario: College of Physicians and Surgeons Ontario (CPSO); 2021.
Joudrey PJ, Adams ZM, Bach P, et al. Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada. JAMA Netw Open. 2021;4(7):e2118223.
Ghosh A, Naskar C, Roub F-E, Basu D. Review of the adaptations in opioid agonist treatment during the COVID-19 pandemic: focus on buprenorphine-based treatment. J Opioid Manag. 2021;17(7):119–31.
Government of Canada. Subsection 56(1) class exemption for patients, practitioners and pharmacists prescribing and providing controlled substances in Canada. Ottawa, Ontario: Government of Canada; 2021.
Green TC, Bratberg J, Finnell DS. Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment. Subst Abuse. 2020;41(2):147–9.
Samuels EA, Clark SA, Wunsch C, et al. Innovation during COVID-19: improving addiction treatment access. J Addict Med. 2020;14(4):e8–9.
Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021;123:108276.
Levander XA, Hoffman KA, McIlveen JW, McCarty D, Terashima JP, Korthuis PT. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addict Sci Clin Pract. 2021;16(1):1–10.
Corace K, Suschinsky K, Wyman J, et al. Evaluating how has care been affected by the Ontario COVID-19 opioid agonist treatment guidance: patients’ and prescribers’ experiences with changes in unsupervised dosing. Int J Drug Policy. 2021;102:103573.
Gomes T, Campbell TJ, Kitchen SA, et al. Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation. JAMA. 2022;327(9):846–55.
My Safe Society. A call for a safer drug supply. https://mysafe.org/. Published 2022. Accessed 28 Mar 2022.